Literature DB >> 30467845

Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.

Christopher P Fox1, Elizabeth H Phillips2, Jeffery Smith3, Kim Linton4, Eve Gallop-Evans5, Claire Hemmaway6, Dorothee P Auer7, Charlotte Fuller8, Andrew J Davies9, Pamela McKay10, Kate Cwynarski2.   

Abstract

Entities:  

Keywords:  diagnosis; diffuse large B-cell lymphoma; intraocular lymphoma; primary CNS lymphoma; staging; treatment

Mesh：

Year:  2018        PMID： 30467845     DOI： 10.1111/bjh.15661

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  25 in total

1.  Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.

Authors:  Heiner Zimmermann; Mirko Nitsche; Christiane Pott; Petra Reinke; Nina Babel; Robert M Hermann; Ingeborg A Hauser; Dennis Hahn; Matthias Ritgen; Claudia Pietschmann; Wolfram Klapper; Ioannis Anagnostopoulos; Ralf U Trappe
Journal:  Ann Hematol       Date:  2021-05-11       Impact factor: 3.673

Review 2.  Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review.

Authors:  Takanori Ichikawa; Yasuhiro Shimojima; Dai Kishida; Tomoki Kaneko; Yoshiki Sekijima
Journal:  Rheumatol Int       Date:  2020-04-06       Impact factor: 2.631

Review 3.  [Guidelines nr. 24a intermediate uveitis].

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

4.  Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma.

Authors:  Tadashi Okamura; Hiroki Hosoi; Takeshi Matsufusa; Yuina Akagi; Ryuta Iwamoto; Hideki Kosako; Shogo Murata; Toshiki Mushino; Shin-Ichi Murata; Takashi Sonoki
Journal:  Ann Hematol       Date:  2022-01-27       Impact factor: 3.673

5.  Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?

Authors:  Thomas Millard; Fatin Sammour; Chloe Anthias; Sandra Easdale; Carlos Gonzalez-Arias; Mark Ethell; Mike Potter; Sunil Iyengar; Dima El-Sharkawi; Ayoma D Attygalle; Ian Chau; David Cunningham; Emma Nicholson; Bhupinder Sharma
Journal:  Bone Marrow Transplant       Date:  2021-10-05       Impact factor: 5.483

6.  Lymphomatosis cerebri: a rare diffuse leukoencephalopathy you should never miss.

Authors:  Yin-Xi Zhang; Jin-Long Tang; Qi-Lun Lai
Journal:  Neurol Sci       Date:  2022-09-24       Impact factor: 3.830

7.  Usefulness of dual isotope 123I-IMP and 201Tl SPECT for the diagnosis of primary central nervous system lymphoma and glioblastoma.

Authors:  Sho Osawa; Masahiko Tosaka; Keishi Horiguchi; Azusa Tokue; Tetsuya Higuchi; Yoshito Tsushima; Yuhei Yoshimoto
Journal:  Int J Clin Oncol       Date:  2022-05-13       Impact factor: 3.850

Review 8.  A case report of primary central nervous system lymphoma.

Authors:  Xu Zeng; Xiaofei Lu; Xinlong Li; Lilei Peng; Ligang Chen
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

9.  A Case of Primary Central Nervous System Lymphoma Mimic Neuromyelitis Optica.

Authors:  Xixi Sheng; Mingwei Xu; Xia Li
Journal:  Transl Neurosci       Date:  2020-02-18       Impact factor: 1.757

10.  Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study.

Authors:  Florian Scheichel; Franz Marhold; Daniel Pinggera; Barbara Kiesel; Tobias Rossmann; Branko Popadic; Adelheid Woehrer; Michael Weber; Melitta Kitzwoegerer; Klaus Geissler; Astrid Dopita; Stefan Oberndorfer; Wolfgang Pfisterer; Christian F Freyschlag; Georg Widhalm; Karl Ungersboeck; Karl Roessler
Journal:  BMC Cancer       Date:  2021-06-29       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.